Durvalumab as third-line or later treatment for advanced non-small-cell lung cancer (ATLANTIC): an open-label, single-arm, phase 2 study
Marina Chiara Garassino(University of Chicago), Inmaculada Ramos García, Antonio Chella(Azienda Ospedaliera Universitaria Pisana), Joo-Hang Kim(CHA University Bundang Medical Center), Akhil Chopra(Johns Hopkins University), Makoto Maemondo(Miyagi Prefectural Hospital Organization), Michael J. Thomas(Harbin Medical University), Veerle Surmont(Ghent University Hospital), C. Chouaïd(Université de Montpellier), Phillip A. Dennis(AVEO Oncology (United States)), Ji‐Youn Han(National Cancer Centre Japan), Raffaele Califano(The Christie NHS Foundation Trust), Cristóbal Belda-Iniesta(Instituto de Salud Carlos III), Wu‐Chou Su(National Cheng Kung University Hospital), Sandrine Hiret(Institut de Cancérologie de l'Ouest), Keunchil Park(The University of Texas MD Anderson Cancer Center), Ross A. Soo(National University Cancer Institute, Singapore), Catherine Wadsworth(AstraZeneca (United Kingdom)), H. Léna(Oncogenesis Stress Signaling), Luis Paz-Ares Rodríguez, Sang‐We Kim(Ulsan College), Héctor Soto Parrà, Paul Wheatley‐Price(University of Ottawa), Yifan Huang(AstraZeneca (United States)), Michele Stanislaw Milella(University of Verona), Julien Mazières(Université Toulouse III - Paul Sabatier), Parneet Cheema(University of Toronto), Martin Reck(German Center for Lung Research), Byoung Chul Cho(Yonsei University), Naiyer A. Rizvi(Synthego (United States)), Esther Holgado Martin, Eckart Laack, Paolo Bidoli(Fondazione IRCCS Istituto Nazionale dei Tumori), Jamie E. Chaft(Memorial Sloan Kettering Cancer Center), John D. Powderly(Carolina BioOncology Institute), Dong‐Wan Kim(Seoul National University Hospital), Jong-Seok Lee(Seoul National University Bundang Hospital), Hideo Saka(Nagoya Medical Center), Young‐Chul Kim(Chonnam National University Hwasun Hospital), Nobuyuki Katakami(Takarazuka City Hospital), Johan Vansteenkiste(KU Leuven), Jesus Corral Jaime(Hospital Universitario Virgen del Rocío), Juergen Wolf(Ente Ospedaliero Cantonale), Yuichiro Oe, G. Robinet(Centre Hospitalier Régional Universitaire de Brest), Peter Schmid(Queen Mary University of London), Silvia Novello(University of Turin), David Vicente Baz(Hospital Universitario Virgen Macarena), Thierry Berghmans(Institut Jules Bordet)
Cited by 579
Related Papers
Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer
|New England Journal of Medicine|2012|12.6k
Gefitinib or Chemotherapy for Non–Small-Cell Lung Cancer with Mutated EGFR
|New England Journal of Medicine|2010|5.6k
Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial
|The Lancet Oncology|2012|5.5k
Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial
|The Lancet|2016|4.8k
Tumor mutational load predicts survival after immunotherapy across multiple cancer types
|Nature Genetics|2019|4.4k